November 9, 2026

For Immediate Release

Company name:	VITAL KSK HOLDINGS, INC.
Representative:	Taisuke Murai, President & CEO
Company address:	1-1-12, Tsurumaki, Setagaya-ku, Tokyo
	(Securities Code: 3151, TSE Prime Market)
Contact:	Kenta Sato, Executive Officer,
	Manager of Corporate Planning Department
	(Tel. +81-3-5787-8565)

Notice Regarding Revision of Full-Year Earnings Forecast for Fiscal Year Ending March 2027

At the Board of Directors meeting held on November 9, 2026, VITAL KSK HOLDINGS, INC. (hereinafter "the Company") resolved to revise the full-year consolidated earnings forecast for the fiscal year ending March 2027, which was announced on May 14, 2026, in light of recent business performance trends, as described below.

1. Revision of the Consolidated Earnings Forecast for the Current Fiscal Year

(1) Revision of Full-Year Consolidated Earnings Forecast for Fiscal Year Ending March 2027 (April 1, 2026 to March 31, 2027)

	Net Sales	Core Operating Profit	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Earnings per Share
Previously Announced Forecast (A)	Million yen 620,000	Million yen 5,700	Million yen 4,100	Million yen 5,000	Million yen 7,500	Yen/sen 155.03
Current Revised Forecast (B)	627,000	3,400	1,800	2,700	6,700	138.50
Change (B-A)	7,000	(2,300)	(2,300)	(2,300)	(800)	—
Rate of Change (%)	1.1	(40.4)	(56.1)	(46.0)	(10.7)	—

(Reference) Previous Fiscal Year Results (Fiscal Year Ended March 2026)	610,497	5,307	4,027	7,822	7,362	152.29

(2) Reasons for the Revision
As announced today, in the consolidated financial results for the first half of the fiscal year, sales in the Pharmaceutical Wholesale Business, the Group's core business, performed steadily due to an increase in sales of high-priced pharmaceuticals, primarily anticancer drugs, and influenza vaccines, among other factors. Full-year net sales are also expected to exceed the previous forecast, as they have been tracking above initial expectations, mainly due to the Pharmaceutical Wholesale Business.

On the other hand, in terms of profit, the operating environment remains challenging, continuing to be affected by the impact of drug price revisions, declines in selling prices due to intensifying market competition, increases in wholesale prices, and decreases in rebates, among other factors. In addition to the decline in gross profit margin resulting from the above factors, as well as an anticipated increase in selling, general and administrative expenses resulting from rising personnel costs and price inflation, and an increase in expenses related to various forward-looking investments, including DX Promotion, and the strengthening of cybersecurity measures, operating income and ordinary income are expected to fall below the previous forecast.

In light of these circumstances, the Company has decided to revise the full-year consolidated financial forecast for the fiscal year ending March 2027, which was announced on May 14, 2026.

(Note) The above forecasts have been prepared based on information available as of the date of announcement of this document, and actual results may differ from the forecasted figures due to various factors.